Bifidobacterium infantis 35624

Bifidobacterium infantis 35624 is a clinically studied probiotic strain that modulates gut microbiota through production of short-chain fatty acids and antimicrobial compounds. This strain specifically reduces inflammatory cytokines and enhances intestinal barrier function to improve digestive health and IBS symptoms.

Origin & History

Bifidobacterium infantis 35624 is a specific strain of probiotic bacteria isolated from the human gastrointestinal tract. It is cultivated under controlled conditions to ensure purity and efficacy. This strain is often used in supplements for its gut health benefits.

Historical & Cultural Context

Bifidobacterium species have been used in fermented foods for centuries. Their discovery in the early 20th century revolutionized the understanding of gut microbiota.

Health Benefits

- Supports digestive health by balancing gut microbiota, enhancing nutrient absorption and reducing bloating. - May reduce symptoms of irritable bowel syndrome by 50%, improving quality of life. - Boosts immune function by increasing production of protective antibodies. - Enhances mental health by producing neurotransmitters like serotonin. - Reduces inflammation by modulating cytokine production, leading to less discomfort. - Improves skin health by reducing systemic inflammation, promoting a clearer complexion. - Aids in weight management by influencing hormones that regulate appetite.

How It Works

B. infantis 35624 produces acetate, propionate, and butyrate short-chain fatty acids that strengthen tight junctions in the intestinal epithelium and reduce pro-inflammatory cytokines IL-6 and TNF-α. The strain synthesizes bacteriocins that inhibit pathogenic bacteria while stimulating regulatory T-cells through Toll-like receptor 2 signaling. It also increases secretory IgA production and enhances mucin secretion by goblet cells.

Scientific Research

Several randomized controlled trials (RCTs) have demonstrated the efficacy of Bifidobacterium infantis 35624 in managing IBS symptoms. Meta-analyses support its role in enhancing gut health and immune function.

Clinical Summary

Multiple randomized controlled trials with 362 IBS patients demonstrated 50% reduction in abdominal pain, bloating, and bowel movement difficulty over 4-8 weeks. A placebo-controlled study of 75 participants showed significant improvements in inflammatory markers including reduced IL-10 and increased anti-inflammatory cytokines. Clinical evidence is robust with consistent outcomes across studies, though most trials were conducted on adults with IBS rather than broader populations.

Nutritional Profile

- Contains live beneficial bacteria.
- Supports production of short-chain fatty acids.
- Contributes to maintaining a healthy gut flora balance.

Preparation & Dosage

Typical dosage ranges from 1-10 billion CFUs daily in capsule or powder form. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus acidophilus, Inulin, FOS

Safety & Interactions

B. infantis 35624 is generally well-tolerated with mild gastrointestinal side effects like temporary gas or bloating in less than 5% of users. No significant drug interactions have been reported, though it may theoretically reduce effectiveness of antibiotics if taken simultaneously. Immunocompromised individuals should consult healthcare providers before use due to theoretical risk of bacteremia. Safety during pregnancy and lactation has not been specifically studied, warranting caution in these populations.